肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：前列腺癌Neo-AAPL治疗与PD-L1表达

2017-11-18 MedSci MedSci原创

前列腺癌Neo-AAPLPD-L1
关注

PD-L1/PD-1阻滞在前列腺癌治疗中是不成功的，可能的原因是前列腺癌免疫原性差以及PD-L1低表达。近期有研究认为有一些前列腺癌可以显着表达PD-L1。而且在临床前模型中激素受体拮抗剂enzalutamide可以上调前列腺癌PD-L1表达。CLIN CANCER RES近期发表了一篇文章，研究新辅助阿比特龙去势治疗联合泼尼松及亮丙瑞林（Neo-AAPL）对前列腺癌PD-L1表达的影响。

PD-L1/PD-1阻滞在前列腺癌治疗中是不成功的，可能的原因是前列腺癌免疫原性差以及PD-L1低表达。近期有研究认为有一些前列腺癌可以显着表达PD-L1。而且在临床前模型中激素受体拮抗剂enzalutamide可以上调前列腺癌PD-L1表达。CLIN CANCER RES近期发表了一篇文章，研究新辅助阿比特龙去势治疗联合泼尼松及亮丙瑞林（Neo-AAPL）对前列腺癌PD-L1表达的影响。研究纳入了44例Neo-AAPL治疗后进行根治性前列腺切除的中-高风险前列腺癌患者标本。收集130例未接受治疗的前列腺肿瘤标本，其中44例为Neo-AAPL的对照组患者。使用免疫组化检测肿瘤PD-L1表达水平。在研究及对照组中研究肿瘤浸润CD8+细胞。在PD-L1阳性肿瘤中分析DNA错配修复基因表达。研究结果表明，Neo-AAPL治疗后的肿瘤与对照组相比有PD-L1阳性降低趋势。治疗后的肿瘤肿瘤浸润CD8+细胞更少。在130例未接受治疗的患者中，非裔美国人，血PSA升高和小前列腺独立预测肿瘤PD-L1阳性。21例PD-L1阳性的患者中有1例存在MSH2表达缺失。文章最后认为，Neo-AAPL治疗不会增

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
    2018-01-20 ylz8410

    #AAP#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
    2018-01-11 lxg951

    #PD-L1表达#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
    2017-11-20 smartjoy

    #PD-L1#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
    2017-11-20 风铃824

    #APL#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
    2017-11-18 明天会更好！

    好消息.值得学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1633203, encodeId=13511633203fd, content=<a href='/topic/show?id=c0bf168341' target=_blank style='color:#2F92EE;'>#AAP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1683, encryptionId=c0bf168341, topicName=AAP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89e022034329, createdName=ylz8410, createdTime=Sat Jan 20 08:06:00 CST 2018, time=2018-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941493, encodeId=bc81194149382, content=<a href='/topic/show?id=da8513930e7' target=_blank style='color:#2F92EE;'>#PD-L1表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13930, encryptionId=da8513930e7, topicName=PD-L1表达)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Thu Jan 11 18:06:00 CST 2018, time=2018-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254941, encodeId=cfb0125494184, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13921, encryptionId=be71139214f, topicName=PD-L1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e76f39, createdName=smartjoy, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509516, encodeId=e11915095167f, content=<a href='/topic/show?id=6a8e264431' target=_blank style='color:#2F92EE;'>#APL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2644, encryptionId=6a8e264431, topicName=APL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c81c10095307, createdName=风铃824, createdTime=Mon Nov 20 01:06:00 CST 2017, time=2017-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262341, encodeId=1aba2623416d, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:39:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262340, encodeId=7934262340d2, content=好消息.值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好！, createdTime=Sat Nov 18 19:38:54 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
    2017-11-18 明天会更好！

    好消息.值得学习

    0

相关资讯

Int J Cancer：异黄酮和拟雌内酯日常摄入与前列腺癌风险分析

实验研究阐释了植物雌激素也许能够调控某些癌症位点的风险，原因是由于他们的结构与17β-雌二醇相似。最近，有研究人员调查了是否这些化合物的摄入能够在人类群体中影响前列腺癌风险。研究人员进行了中值为11.5年的跟踪调查，在前列腺、肺、结肠和卵巢癌筛选试验中，27004名男性中鉴定出了2598个前列腺癌案例，并包括了287个晚期案例。研究人员利用食物频率调查问卷评估了植物雌激素（除了木酚素）的日常摄入，

Brit J Cancer：Sox5能够促进前列腺转移！

转移性去势难治性前列腺癌（mCRPC）是导致前列腺癌病人死亡的主要贡献者之一。到目前为止，阐释mCRPC的详细分子机制仍旧不清楚。在已知的表皮-间质转化（EMT）在癌症转移中具有关键的作用情况下，研究人员在mCRPC中，进行了旨在分析转化生长因子-beta（TGF-β）信号相关的蛋白Sox5的表达和功能情况。研究人员利用蛋白免疫印迹和免疫组化技术及免疫荧光技术对蛋白表达水平进行了分析，并利用荧光素

Prostate：前列腺癌中的雌激素受体信号分析

雄激素受体（AR）是前列腺癌预防和治疗的经典靶标。但是，有研究表明雌激素和它们的受体同样涉及到了前列腺癌发展和肿瘤恶化。最近，有研究人员回顾了最近的实验和临床数据，从而来阐释雌激素和它们的受体对前列腺致瘤和肿瘤恶化产生作用的病理机制。研究发现，雌激素受体(ERβ)是人类前列腺中最普遍的ER，然而雌激素受体（ERα）的分布限制在前列腺上皮基底细胞和基质细胞中。在高等级前列腺上皮内瘤（HGPIN）中，

CLIN CANCER RES：新辅助多西他赛联合去势治疗对高风险前列腺癌基因组学和转录组学的影响

多西他赛联合去势治疗已成为转移性前列腺癌的标准治疗方式。近期进行的临床试验CALGB 90203主要的目的观察这一治疗方式在疾病早期的临床效果。在临床试验中获得的标本为探索多西他赛联合去势治疗的分子反应及可能的分子标志提供了机会。CLIN CANCER RES近期发表了一篇文章，研究了这一问题。

Prostate：高风险前列腺癌病人在首发症状时的预后参数分析

高风险前列腺癌可以由病人的格林森得分（GS）、前列腺特异性抗原水平（PSA）和临床T（cT）阶段进行确定，但是由于该病的异质性，一个新的标记是需要的。最近，有研究人员评估了在患有高风险前列腺癌病人中，是否由穿刺活检确定的前列腺导管内癌（IDC-P）是无进展自由生存（PFS）和癌症特异生存（CSS）的不良预后参数。研究人员回顾性的评估了1991年到2005年经历根治性前列腺癌切除术的患有高风险前列腺

Scand J Urol：爱沙尼亚前列腺发生率、死亡率和生存趋势分析

最近，有研究人员进行了旨在分析爱沙尼亚前列腺癌（PCa）发生率、死亡率和生存长期趋势的研究，并且特别关注了年龄和阶段参数。研究人员分别从爱沙尼亚癌症登记处和死亡原因登记处获得了1995年到2014年的PCa发生案例数据和有关的死亡数据，并利用连接点回归评估了发生和死亡比例的每年变化趋势。研究人员还推算出了5年的相对生存率（RSRs），并通过年龄和阶段对发生率和生存进行了分析。研究发现，2010-2